Multiple Myeloma
Conditions
Brief summary
At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. When contacted by a treating physician, BMS will consider requests for providing early patient access to Elotuzumab in patients with multiple myeloma who are residents of Belgium, Thailand, Turkey, Argentina, and Colombia.
Detailed description
Choosing to participate in an early patient access program is an important personal decision. Talk with your doctor and family members or friends about deciding to participate in an early patient access program. To learn more about early patient access programs, your doctor may contact BMS using the information provided below.
Interventions
BIOLOGICALElotuzumab
Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.
Sponsors
Bristol-Myers Squibb
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
Specific eligibility criteria must be met for access outside of a clinical trial. These inclusion criteria include: * The illness must be serious or life threatening * There are no other viable options (including approved products or active clinical trials) * There is sufficient evidence that the potential benefit to the patient would likely outweigh the potential risks based on what is known at the time * Other defined inclusion/
Exclusion criteria
could be applicable.
Outcome results
None listed